Ex-Googlers strike startup gold—again—with $1.9 billion sale to drugs giant

February 19, 2018 by Ethan Baron, The Mercury News

A two-man entrepreneurial team who attended an elite college together where they founded a startup they sold to Google for a reported $81 million have just sold a second company they founded together for nearly $2 billion.

Swiss pharmaceutical giant Roche and the cancer-technology firm Flatiron founded by Nat Turner and Zach Weinberg confirmed the $1.9 billion deal Thursday that Roche said would speed development of new cancer treatments and help it with regulators.

Flatiron, a privately held backed by Google Ventures (now GV), sells data management and analytics software to cancer clinics, research centers and life-science companies. It has collaborated with the Food and Drug Administration and makes software for the keeping of , a product subject to close regulatory scrutiny. Roche makes a number of leading cancer drugs.

"As part of the acquisition, Roche is committing additional resources to Flatiron so that we can continue on our mission and have an even greater impact," Flatiron CEO Turner said in a company blog post.

Flatiron will operate separately beside other Roche business units, Turner said.

Turner and Flatiron president Weinberg went through The Wharton School's undergraduate economics program together. Before graduating from the Pennsylvania business school in 2008 they began work on the advertising-technology startup, Invite Media, that they would sell to Google in 2010 for a reported $81 million.

Mountain View search and digital-ads giant Google integrated Invite's platforms into its DoubleClick ad-tech division, and kept Turner and Weinberg on as product managers for two years before they left to start up the New York-based Flatiron.

Roche, which already owned about 13 percent of Flatiron, called its purchase "an important step" toward hurrying up development of new treatments.

The acquisition was about more than software, Roche said in a statement.

"Flatiron Health has worked with industry leaders and regulators to develop new approaches for how real-world evidence may be used in regulatory decision making," Roche said.

The deal is expected to close by the end of June, Roche said.

Explore further: Roche targets tumours with Ignyta purchase

10 shares

Related Stories

Roche targets tumours with Ignyta purchase

December 22, 2017

Roche, the world's top cancer drug maker, announced Friday it had agreed to buy US firm Ignyta, which is developing a treatment against some tumours, for $1.7 billion (1.4 billion euros).

FDA gives green light to Roche cancer test

December 4, 2017

The US Food and Drug Administration has given the green light to Roche for its FoundationOne CDx personalised diagnostic cancer test, the Swiss group said Monday.

Roche buying Seragon in US for up to $1.7 billion

July 2, 2014

Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments.

Roche taking majority in Foundation Medicine for $1.03B

January 12, 2015

Roche is taking a majority stake in U.S.-based Foundation Medicine in a deal worth $1.03 billion that the Swiss pharmaceutical company says will help it to develop new treatment options for cancer patients.

Recommended for you

Apple closing iPhone security gap used by law enforcement

June 14, 2018

Apple is closing a security gap that allowed outsiders to pry personal information from locked iPhones without a password, a change that will thwart law enforcement agencies that have been exploiting the vulnerability to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.